Synlogic (SYBX) Projected to Post Earnings on Tuesday

Synlogic (NASDAQ:SYBX) is anticipated to post its quarterly earnings results on Tuesday, March 18th. Analysts expect Synlogic to post earnings of ($0.10) per share for the quarter.

Synlogic (NASDAQ:SYBX) last released its earnings results on Thursday, March 6th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. On average, analysts expect Synlogic to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Synlogic Stock Performance

Synlogic stock opened at $1.24 on Monday. Synlogic has a one year low of $1.15 and a one year high of $2.04. The business has a fifty day moving average of $1.38 and a two-hundred day moving average of $1.42. The company has a market cap of $14.44 million, a P/E ratio of -0.30 and a beta of 0.72.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.